메뉴 건너뛰기




Volumn 347, Issue 2, 2014, Pages 151-158

New and emerging risk factors for coronary heart disease

Author keywords

C reactive protein; Carotid intimal media thickness; Coronary artery calcium score; Coronary heart disease; Lipoprotein (a)

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FARNESOID X RECEPTOR; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA;

EID: 84894203224     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31828aab45     Document Type: Review
Times cited : (46)

References (129)
  • 1
    • 84855396777 scopus 로고    scopus 로고
    • Executive summary: Heart disease and stroke statistics-2012 update: A report from the American Heart Association
    • Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012;125:188-97.
    • (2012) Circulation , vol.125 , pp. 188-197
    • Roger, V.L.1    Go, A.S.2    Lloyd-Jones, D.M.3
  • 2
    • 0038706687 scopus 로고    scopus 로고
    • Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:143-3421.
    • (2002) Circulation , vol.106 , pp. 143-3421
  • 3
    • 0019192770 scopus 로고
    • The diagnostic and prognostic significance of coronary artery calcification. A report of 800 cases
    • Margolis JR, Chen JT, Kong Y, et al. The diagnostic and prognostic significance of coronary artery calcification. A report of 800 cases. Radiology 1980;137:609-16.
    • (1980) Radiology , vol.137 , pp. 609-616
    • Margolis, J.R.1    Chen, J.T.2    Kong, Y.3
  • 4
    • 0028910752 scopus 로고
    • Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Effect of patient's sex on diagnosis
    • Rumberger JA, Sheedy PF III, Breen JF, et al. Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Effect of patient's sex on diagnosis. Circulation 1995;91:1363-67.
    • (1995) Circulation , vol.91 , pp. 1363-1367
    • Rumberger, J.A.1    Sheedy III, P.F.2    Breen, J.F.3
  • 5
    • 9044240472 scopus 로고    scopus 로고
    • Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study
    • Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study. Circulation 1996;93:898-904.
    • (1996) Circulation , vol.93 , pp. 898-904
    • Budoff, M.J.1    Georgiou, D.2    Brody, A.3
  • 6
    • 0035953113 scopus 로고    scopus 로고
    • Electron-beam computed tomography in the diagnosis of coronary artery disease: A meta-Analysis
    • Nallamothu BK, Saint S, Bielak LF, et al. Electron-beam computed tomography in the diagnosis of coronary artery disease: A meta-Analysis. Arch Intern Med 2001;161:833-38.
    • (2001) Arch Intern Med , vol.161 , pp. 833-838
    • Nallamothu, B.K.1    Saint, S.2    Bielak, L.F.3
  • 7
    • 0035137052 scopus 로고    scopus 로고
    • Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: Results of 1,764 patients
    • Haberl R, Becker A, Leber A, et al. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: Results of 1,764 patients. J Am Coll Cardiol 2001;37:451-57.
    • (2001) J Am Coll Cardiol , vol.37 , pp. 451-457
    • Haberl, R.1    Becker, A.2    Leber, A.3
  • 8
    • 0025342374 scopus 로고
    • Quantification of coronary artery calcium using ultrafast computed tomography
    • Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
    • (1990) J Am Coll Cardiol , vol.15 , pp. 827-832
    • Agatston, A.S.1    Janowitz, W.R.2    Hildner, F.J.3
  • 9
    • 41449112372 scopus 로고    scopus 로고
    • Coronary calcium as a predictor of coronary events in four racial or ethnic groups
    • Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336-45.
    • (2008) N Engl J Med , vol.358 , pp. 1336-1345
    • Detrano, R.1    Guerci, A.D.2    Carr, J.J.3
  • 10
    • 82455212893 scopus 로고    scopus 로고
    • Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: Results from the CONFIRM (coronary CT angiography evaluation for clinical outcomes: An international multicenter) registry
    • Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: Results from the CONFIRM (coronary CT angiography evaluation for clinical outcomes: An international multicenter) registry. J Am Coll Cardiol 2011;58:2533-40.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 2533-2540
    • Villines, T.C.1    Hulten, E.A.2    Shaw, L.J.3
  • 11
    • 66449095849 scopus 로고    scopus 로고
    • Diagnostic and prognostic value of absence of coronary artery calcification
    • Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging 2009;2:675-88.
    • (2009) JACC Cardiovasc Imaging , vol.2 , pp. 675-688
    • Sarwar, A.1    Shaw, L.J.2    Shapiro, M.D.3
  • 12
    • 33644865949 scopus 로고    scopus 로고
    • Distribution of coronary artery calcium by race, gender, and age: Results from the multiethnic study of atherosclerosis (MESA)
    • McClelland RL, Chung H, Detrano R, et al. Distribution of coronary artery calcium by race, gender, and age: Results from the multiethnic study of atherosclerosis (MESA). Circulation 2006;113:30-7.
    • (2006) Circulation , vol.113 , pp. 30-37
    • McClelland, R.L.1    Chung, H.2    Detrano, R.3
  • 13
    • 84858306926 scopus 로고    scopus 로고
    • Evaluation of newer risk markers for coronary heart disease risk classification: A cohort study
    • Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: A cohort study. Ann Intern Med 2012;156:438-44.
    • (2012) Ann Intern Med , vol.156 , pp. 438-444
    • Kavousi, M.1    Elias-Smale, S.2    Rutten, J.H.3
  • 14
    • 34247546061 scopus 로고    scopus 로고
    • Long-Term prognosis associated with coronary calcification: Observations from a registry of 25,253 patients
    • Budoff MJ, Shaw LJ, Liu ST, et al. Long-Term prognosis associated with coronary calcification: Observations from a registry of 25,253 patients. J Am Coll Cardiol 2007;49:1860-70.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1860-1870
    • Budoff, M.J.1    Shaw, L.J.2    Liu, S.T.3
  • 15
    • 77951639385 scopus 로고    scopus 로고
    • Coronary artery calcium score and risk classification for coronary heart disease prediction
    • Polonsky TS,McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010;303:1610-16.
    • (2010) JAMA , vol.303 , pp. 1610-1616
    • Polonsky, T.S.1    McClelland, R.L.2    Jorgensen, N.W.3
  • 16
    • 0037512312 scopus 로고    scopus 로고
    • Electron-beam tomography coronary artery calcium and cardiac events: A 37-month follow-up of 5635 initially asymptomatic low-To intermediate-risk adults
    • Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: A 37-month follow-up of 5635 initially asymptomatic low-To intermediate-risk adults. Circulation 2003;107:2571-76.
    • (2003) Circulation , vol.107 , pp. 2571-2576
    • Kondos, G.T.1    Hoff, J.A.2    Sevrukov, A.3
  • 17
    • 0347722500 scopus 로고    scopus 로고
    • Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals
    • Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-15.
    • (2004) JAMA , vol.291 , pp. 210-215
    • Greenland, P.1    LaBree, L.2    Azen, S.P.3
  • 18
    • 0029949496 scopus 로고    scopus 로고
    • Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects
    • Arad Y, Spadaro LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation 1996;93:1951-53.
    • (1996) Circulation , vol.93 , pp. 1951-1953
    • Arad, Y.1    Spadaro, L.A.2    Goodman, K.3
  • 19
    • 20444373191 scopus 로고    scopus 로고
    • Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: The St. Francis heart study
    • Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: The St. Francis Heart Study. J Am Coll Cardiol 2005;46:158-65.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 158-165
    • Arad, Y.1    Goodman, K.J.2    Roth, M.3
  • 20
    • 27644504593 scopus 로고    scopus 로고
    • Detection of high-risk young adults and women by coronary calcium and national cholesterol education program panel iii guidelines
    • Nasir K, Michos ED, Blumenthal RS, et al. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. J Am Coll Cardiol 2005; 46:1931-36.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1931-1936
    • Nasir, K.1    Michos, E.D.2    Blumenthal, R.S.3
  • 21
    • 37149016813 scopus 로고    scopus 로고
    • Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: The multi-ethnic study of atherosclerosis (MESA)
    • Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: The multi-ethnic study of atherosclerosis (MESA). Arch Intern Med 2007;167:2437-42.
    • (2007) Arch Intern Med , vol.167 , pp. 2437-2442
    • Lakoski, S.G.1    Greenland, P.2    Wong, N.D.3
  • 22
    • 84655169207 scopus 로고    scopus 로고
    • Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: A systematic review
    • Peters SA, den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: A systematic review. Heart 2012;98:177-84.
    • (2012) Heart , vol.98 , pp. 177-184
    • Peters, S.A.1    Den Ruijter, H.M.2    Bots, M.L.3
  • 23
    • 20444407053 scopus 로고    scopus 로고
    • Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: The St. Francis Heart Study randomized clinical trial
    • Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005;46:166-72.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 166-172
    • Arad, Y.1    Spadaro, L.A.2    Roth, M.3
  • 24
    • 84858325566 scopus 로고    scopus 로고
    • Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treat-ment: A post hoc analysis from the st francis heart study
    • Mulders TA, Sivapalaratnam S, Stroes ES, et al. Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treat-ment: A post hoc analysis from the St. Francis Heart Study. JACC Cardiovasc Imaging 2012;5:252-60.
    • (2012) JACC Cardiovasc Imaging , vol.5 , pp. 252-260
    • Mulders, T.A.1    Sivapalaratnam, S.2    Stroes, E.S.3
  • 25
    • 3042817122 scopus 로고    scopus 로고
    • Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterollowering therapy
    • Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterollowering therapy. Arterioscler Thromb Vasc Biol 2004;24:1272-77.
    • (2004) Arterioscler Thromb Vasc Biol , vol.24 , pp. 1272-1277
    • Raggi, P.1    Callister, T.Q.2    Shaw, L.J.3
  • 26
    • 84865320778 scopus 로고    scopus 로고
    • Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals
    • Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308:788-95.
    • (2012) JAMA , vol.308 , pp. 788-795
    • Yeboah, J.1    McClelland, R.L.2    Polonsky, T.S.3
  • 27
    • 33645464935 scopus 로고    scopus 로고
    • Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers
    • Shaw LJ, Raggi P, Callister TQ, et al. Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers. Eur Heart J 2006;27:968-75.
    • (2006) Eur Heart J , vol.27 , pp. 968-975
    • Shaw, L.J.1    Raggi, P.2    Callister, T.Q.3
  • 28
    • 79956118515 scopus 로고    scopus 로고
    • Coronary calcium score and prediction of all-cause mortality in diabetes: The diabetes heart study
    • Agarwal S, Morgan T, Herrington DM, et al. Coronary calcium score and prediction of all-cause mortality in diabetes: The diabetes heart study. Diabetes Care 2011;34:1219-24.
    • (2011) Diabetes Care , vol.34 , pp. 1219-1224
    • Agarwal, S.1    Morgan, T.2    Herrington, D.M.3
  • 29
    • 78650041424 scopus 로고    scopus 로고
    • 2010 accf/aha guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the american college of cardiology foundation/american heart association task force on practice guidelines
    • Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56: E50-103.
    • (2010) J Am Coll Cardiol , vol.56
    • Greenland, P.1    Alpert, J.S.2    Beller, G.A.3
  • 30
    • 84856284437 scopus 로고    scopus 로고
    • Interpreting the coronary-Artery calcium score
    • Grayburn PA. Interpreting the coronary-Artery calcium score. N Engl J Med 2012;366:294-6.
    • (2012) N Engl J Med , vol.366 , pp. 294-296
    • Grayburn, P.A.1
  • 31
    • 17644412023 scopus 로고    scopus 로고
    • Inflammation, atherosclerosis, and coronary artery disease
    • Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
    • (2005) N Engl J Med , vol.352 , pp. 1685-1695
    • Hansson, G.K.1
  • 32
    • 70450189795 scopus 로고    scopus 로고
    • Inflammation in atherosclerosis: From pathophysiology to practice
    • Leducq Transatlantic Network on Atherothrombosis.
    • Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 2129-2138
    • Libby, P.1    Ridker, P.M.2    Hansson, G.K.3
  • 33
    • 81255188900 scopus 로고    scopus 로고
    • Atherosclerosis: Current pathogenesis and therapeutic options
    • Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22.
    • (2011) Nat Med , vol.17 , pp. 1410-1422
    • Weber, C.1    Noels, H.2
  • 34
    • 26044483536 scopus 로고    scopus 로고
    • C-reactive protein: Ligands, receptors and role in inflammation
    • Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. Clin Immunol 2005;117:104-11.
    • (2005) Clin Immunol , vol.117 , pp. 104-111
    • Marnell, L.1    Mold, C.2    Du Clos, T.W.3
  • 35
    • 79952069515 scopus 로고    scopus 로고
    • Meta-Analysis of genomewide association studies in .80,000 subjects identifies multiple loci for C-reactive protein levels
    • Dehghan A, Dupuis J, Barbalic M, et al. Meta-Analysis of genomewide association studies in .80,000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011;123:731-8.
    • (2011) Circulation , vol.123 , pp. 731-738
    • Dehghan, A.1    Dupuis, J.2    Barbalic, M.3
  • 36
    • 67649961412 scopus 로고    scopus 로고
    • Genetic loci associated with C-reactive protein levels and risk of coronary heart disease
    • Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
    • (2009) JAMA , vol.302 , pp. 37-48
    • Elliott, P.1    Chambers, J.C.2    Zhang, W.3
  • 37
    • 55249087635 scopus 로고    scopus 로고
    • Genetically elevated C-reactive protein and ischemic vascular disease
    • Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897-1908.
    • (2008) N Engl J Med , vol.359 , pp. 1897-1908
    • Zacho, J.1    Tybjaerg-Hansen, A.2    Jensen, J.S.3
  • 38
    • 0037469232 scopus 로고    scopus 로고
    • Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the american heart association
    • Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
    • (2003) Circulation , vol.107 , pp. 499-511
    • Pearson, T.A.1    Mensah, G.A.2    Alexander, R.W.3
  • 39
    • 22844432451 scopus 로고    scopus 로고
    • Race and gender differences in C-reactive protein levels
    • Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005;46:464-9.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 464-469
    • Khera, A.1    McGuire, D.K.2    Murphy, S.A.3
  • 40
    • 78649342368 scopus 로고    scopus 로고
    • Ancestry as a determinant of mean population C-reactive protein values: Implications for cardiovascular risk prediction
    • Shah T, Newcombe P, Smeeth L, et al. Ancestry as a determinant of mean population C-reactive protein values: Implications for cardiovascular risk prediction. Circ Cardiovasc Genet 2010;3:436-44.
    • (2010) Circ Cardiovasc Genet , vol.3 , pp. 436-444
    • Shah, T.1    Newcombe, P.2    Smeeth, L.3
  • 41
    • 0030956673 scopus 로고    scopus 로고
    • Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
    • Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-79.
    • (1997) N Engl J Med , vol.336 , pp. 973-979
    • Ridker, P.M.1    Cushman, M.2    Stampfer, M.J.3
  • 42
    • 0032566401 scopus 로고    scopus 로고
    • Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
    • Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
    • (1998) Circulation , vol.98 , pp. 731-733
    • Ridker, P.M.1    Buring, J.E.2    Shih, J.3
  • 43
    • 1842587885 scopus 로고    scopus 로고
    • C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
    • Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
    • (2004) N Engl J Med , vol.350 , pp. 1387-1397
    • Danesh, J.1    Wheeler, J.G.2    Hirschfield, G.M.3
  • 44
    • 1642277853 scopus 로고    scopus 로고
    • C-reactive protein modulates risk prediction based on the Framingham score: Implications for future risk assessment: Results from a large cohort study in southern Germany
    • Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham score: Implications for future risk assessment: Results from a large cohort study in southern Germany. Circulation 2004;109:1349-53.
    • (2004) Circulation , vol.109 , pp. 1349-1353
    • Koenig, W.1    Lowel, H.2    Baumert, J.3
  • 45
    • 21844451117 scopus 로고    scopus 로고
    • C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study
    • Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005;112:25-31.
    • (2005) Circulation , vol.112 , pp. 25-31
    • Cushman, M.1    Arnold, A.M.2    Psaty, B.M.3
  • 46
    • 59649121465 scopus 로고    scopus 로고
    • C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study
    • Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-7.
    • (2008) Circ Cardiovasc Qual Outcomes , vol.1 , pp. 92-97
    • Wilson, P.W.1    Pencina, M.2    Jacques, P.3
  • 47
    • 84867164377 scopus 로고    scopus 로고
    • C-reactive protein, fibrinogen, and cardiovascular disease prediction
    • Emerging Risk Factors Collaboration
    • Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20.
    • (2012) N Engl J Med , vol.367 , pp. 1310-1320
    • Kaptoge, S.1    Di Angelantonio, E.2
  • 48
    • 0032568486 scopus 로고    scopus 로고
    • C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
    • Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
    • (1998) Circulation , vol.97 , pp. 2007-2011
    • Ridker, P.M.1    Glynn, R.J.2    Hennekens, C.H.3
  • 49
    • 0034704893 scopus 로고    scopus 로고
    • C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
    • Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
    • (2000) N Engl J Med , vol.342 , pp. 836-843
    • Ridker, P.M.1    Hennekens, C.H.2    Buring, J.E.3
  • 50
    • 0037078969 scopus 로고    scopus 로고
    • Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
    • Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
    • (2002) N Engl J Med , vol.347 , pp. 1557-1565
    • Ridker, P.M.1    Rifai, N.2    Rose, L.3
  • 51
    • 0037190065 scopus 로고    scopus 로고
    • Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study
    • Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA 2002;288:980-7.
    • (2002) JAMA , vol.288 , pp. 980-987
    • Pradhan, A.D.1    Manson, J.E.2    Rossouw, J.E.3
  • 52
    • 19944429519 scopus 로고    scopus 로고
    • Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    • Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
    • (2005) N Engl J Med , vol.352 , pp. 29-38
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 53
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • JUPITER Study Group
    • Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 54
    • 77958507050 scopus 로고    scopus 로고
    • Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate-And lowcardiovascular-risk individuals for statin therapy
    • Lee KK, Cipriano LE, Owens DK, et al. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate-And lowcardiovascular-risk individuals for statin therapy. Circulation 2010; 122:1478-87.
    • (2010) Circulation , vol.122 , pp. 1478-1487
    • Lee, K.K.1    Cipriano, L.E.2    Owens, D.K.3
  • 55
    • 0023636242 scopus 로고
    • CDNA sequence of human apolipoprotein(a) is homologous to plasminogen
    • McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-7.
    • (1987) Nature , vol.330 , pp. 132-137
    • McLean, J.W.1    Tomlinson, J.E.2    Kuang, W.J.3
  • 56
    • 0030451016 scopus 로고    scopus 로고
    • Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans
    • Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996;37:2569-85.
    • (1996) J Lipid Res , vol.37 , pp. 2569-2585
    • Marcovina, S.M.1    Albers, J.J.2    Wijsman, E.3
  • 57
    • 0026667073 scopus 로고
    • Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations
    • Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992;90:52-60.
    • (1992) J Clin Invest , vol.90 , pp. 52-60
    • Boerwinkle, E.1    Leffert, C.C.2    Lin, J.3
  • 58
    • 73549097512 scopus 로고    scopus 로고
    • Genetic variants associated with Lp(a) lipoprotein level and coronary disease
    • Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-28.
    • (2009) N Engl J Med , vol.361 , pp. 2518-2528
    • Clarke, R.1    Peden, J.F.2    Hopewell, J.C.3
  • 59
    • 79551551096 scopus 로고    scopus 로고
    • Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans
    • Deo RC, Wilson JG, Xing C, et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One 2011;6:e14581.
    • (2011) PLoS One , vol.6
    • Deo, R.C.1    Wilson, J.G.2    Xing, C.3
  • 60
    • 0242331117 scopus 로고    scopus 로고
    • Report of the national heart Lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: Recent advances and future directions
    • Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions. Clin Chem 2003;49:1785-96.
    • (2003) Clin Chem , vol.49 , pp. 1785-1796
    • Marcovina, S.M.1    Koschinsky, M.L.2    Albers, J.J.3
  • 61
    • 67651210632 scopus 로고    scopus 로고
    • Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
    • Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
    • (2009) JAMA , vol.302 , pp. 412-423
    • Emerging Risk Factors Collaboration Erqou, S.1    Kaptoge, S.2
  • 62
    • 38049177286 scopus 로고    scopus 로고
    • Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study
    • Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008;117:176-84.
    • (2008) Circulation , vol.117 , pp. 176-184
    • Kamstrup, P.R.1    Benn, M.2    Tybjaerg-Hansen, A.3
  • 63
    • 41549133097 scopus 로고    scopus 로고
    • Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data
    • Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Arch Intern Med 2008;168:598-608.
    • (2008) Arch Intern Med , vol.168 , pp. 598-608
    • Bennet, A.1    Di Angelantonio, E.2    Erqou, S.3
  • 64
    • 0033558250 scopus 로고    scopus 로고
    • Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease
    • Dangas G, Ambrose JA, D'Agate DJ, et al. Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am J Cardiol 1999;83:583-5.
    • (1999) Am J Cardiol , vol.83 , pp. 583-585
    • Dangas, G.1    Ambrose, J.A.2    D'Agate, D.J.3
  • 65
    • 84865120887 scopus 로고    scopus 로고
    • Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies
    • Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60:716-21.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 716-721
    • Tsimikas, S.1    Hall, J.L.2
  • 66
    • 84865125773 scopus 로고    scopus 로고
    • Apolipoprotein (a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism
    • Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein (a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012;60:722-9.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 722-729
    • Helgadottir, A.1    Gretarsdottir, S.2    Thorleifsson, G.3
  • 67
    • 84862502750 scopus 로고    scopus 로고
    • Lipid-related markers and cardiovascular disease prediction
    • Emerging Risk Factors Collaboration
    • Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-506.
    • (2012) JAMA , vol.307 , pp. 2499-2506
    • Di Angelantonio, E.1    Gao, P.2
  • 68
    • 33748904095 scopus 로고    scopus 로고
    • Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women
    • Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006;296:1363-70.
    • (2006) JAMA , vol.296 , pp. 1363-1370
    • Suk Danik, J.1    Rifai, N.2    Buring, J.E.3
  • 69
    • 84856101806 scopus 로고    scopus 로고
    • Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: The atherosclerosis risk in communities (aric) study
    • Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012;125:241-9.
    • (2012) Circulation , vol.125 , pp. 241-249
    • Virani, S.S.1    Brautbar, A.2    Davis, B.C.3
  • 70
    • 0034708959 scopus 로고    scopus 로고
    • Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol niaspan-gemfibrozil study group
    • Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160:1177-84.
    • (2000) Arch Intern Med , vol.160 , pp. 1177-1184
    • Guyton, J.R.1    Blazing, M.A.2    Hagar, J.3
  • 71
    • 84861309590 scopus 로고    scopus 로고
    • Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups
    • Bays HE, Shah A, Lin J, et al. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. Am J Cardiovasc Drugs 2012;12:197-206.
    • (2012) Am J Cardiovasc Drugs , vol.12 , pp. 197-206
    • Bays, H.E.1    Shah, A.2    Lin, J.3
  • 72
    • 33847005410 scopus 로고    scopus 로고
    • Apheresis in coronary heart disease with elevated Lp (a): A review of Lp (a) as a risk factor and its management
    • Keller C. Apheresis in coronary heart disease with elevated Lp (a): A review of Lp (a) as a risk factor and its management. Ther Apher Dial 2007;11:2-8.
    • (2007) Ther Apher Dial , vol.11 , pp. 2-8
    • Keller, C.1
  • 73
    • 0029103672 scopus 로고
    • Familial Hypercholesterolaemia Regression Study: A randomised trial of low-densitylipoprotein apheresis
    • Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: A randomised trial of low-densitylipoprotein apheresis. Lancet 1995;345:811-6.
    • (1995) Lancet , vol.345 , pp. 811-816
    • Thompson, G.R.1    Maher, V.M.2    Matthews, S.3
  • 74
    • 0043169544 scopus 로고    scopus 로고
    • Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia
    • van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003;89:893-6.
    • (2003) Heart , vol.89 , pp. 893-896
    • Van Wissen, S.1    Smilde, T.J.2    Trip, M.D.3
  • 75
    • 0036802128 scopus 로고    scopus 로고
    • Atorvastatin lowers lipoprotein (a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk
    • Gonbert S, Malinsky S, Sposito AC, et al. Atorvastatin lowers lipoprotein (a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002;164: 305-11.
    • (2002) Atherosclerosis , vol.164 , pp. 305-311
    • Gonbert, S.1    Malinsky, S.2    Sposito, A.C.3
  • 76
    • 79955066200 scopus 로고    scopus 로고
    • Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial
    • Hernandez C, Francisco G, Ciudin A, et al. Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial. Diabetes Metab 2011;37:124-30.
    • (2011) Diabetes Metab , vol.37 , pp. 124-130
    • Hernandez, C.1    Francisco, G.2    Ciudin, A.3
  • 77
    • 4544346640 scopus 로고    scopus 로고
    • High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
    • Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110: 1406-12.
    • (2004) Circulation , vol.110 , pp. 1406-1412
    • Tsimikas, S.1    Witztum, J.L.2    Miller, E.R.3
  • 78
    • 0036803259 scopus 로고    scopus 로고
    • Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects
    • Schaefer EJ, McNamara JR, Tayler T, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002;90:689-96.
    • (2002) Am J Cardiol , vol.90 , pp. 689-696
    • Schaefer, E.J.1    McNamara, J.R.2    Tayler, T.3
  • 79
    • 84855849500 scopus 로고    scopus 로고
    • Atorvastatin decreases lipoprotein(a): A metaanalysis of randomized trials
    • Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): A metaanalysis of randomized trials. Int J Cardiol 2012;154:183-6.
    • (2012) Int J Cardiol , vol.154 , pp. 183-186
    • Takagi, H.1    Umemoto, T.2
  • 80
    • 84860271201 scopus 로고    scopus 로고
    • Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a)
    • Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a). J Lipid Res 2012;53:1000-11.
    • (2012) J Lipid Res , vol.53 , pp. 1000-1011
    • Deshmukh, H.A.1    Colhoun, H.M.2    Johnson, T.3
  • 81
    • 38849179382 scopus 로고    scopus 로고
    • Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the diabetes and combined lipid therapy regimen study)
    • May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008;101:486-9.
    • (2008) Am J Cardiol , vol.101 , pp. 486-489
    • May, H.T.1    Anderson, J.L.2    Pearson, R.R.3
  • 82
    • 79953699040 scopus 로고    scopus 로고
    • Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice
    • Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57:1611-21.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1611-1621
    • Merki, E.1    Graham, M.2    Taleb, A.3
  • 83
    • 80052380574 scopus 로고    scopus 로고
    • Farnesoid X receptor represses hepatic human APOA gene expression
    • Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011;121:3724-34.
    • (2011) J Clin Invest , vol.121 , pp. 3724-3734
    • Chennamsetty, I.1    Claudel, T.2    Kostner, K.M.3
  • 84
    • 78649888517 scopus 로고    scopus 로고
    • Lipoprotein(a) as a cardiovascular risk factor: Current status
    • Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31:2844-53.
    • (2010) Eur Heart J , vol.31 , pp. 2844-2853
    • Nordestgaard, B.G.1    Chapman, M.J.2    Ray, K.3
  • 85
    • 80053914425 scopus 로고    scopus 로고
    • Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
    • Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. J Clin Lipidol 2011;5:338-67.
    • (2011) J Clin Lipidol , vol.5 , pp. 338-367
    • Davidson, M.H.1    Ballantyne, C.M.2    Jacobson, T.A.3
  • 86
    • 0032519844 scopus 로고    scopus 로고
    • The role of carotid arterial intima-media thickness in predicting clinical coronary events
    • Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9.
    • (1998) Ann Intern Med , vol.128 , pp. 262-269
    • Hodis, H.N.1    Mack, W.J.2    LaBree, L.3
  • 87
    • 33846609195 scopus 로고    scopus 로고
    • Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-Analysis
    • Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-Analysis. Circulation 2007;115:459-67.
    • (2007) Circulation , vol.115 , pp. 459-467
    • Lorenz, M.W.1    Markus, H.S.2    Bots, M.L.3
  • 88
    • 84894169031 scopus 로고    scopus 로고
    • Effect of statin therapy on the progression of common carotid artery intima-media thickness: An updated systematic review and meta-Analysis of randomized controlled trials
    • In press
    • Huang Y, Li W, Dong L, et al. Effect of statin therapy on the progression of common carotid artery intima-media thickness: An updated systematic review and meta-Analysis of randomized controlled trials. J Atheroscler Thromb In press.
    • J Atheroscler Thromb
    • Huang, Y.1    Li, W.2    Dong, L.3
  • 89
    • 77956864643 scopus 로고    scopus 로고
    • Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: A meta-Analysis of randomized controlled trials
    • Bedi US, Singh M, Singh PP, et al. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: A meta-Analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2010;15:268-73.
    • (2010) J Cardiovasc Pharmacol Ther , vol.15 , pp. 268-273
    • Bedi, U.S.1    Singh, M.2    Singh, P.P.3
  • 90
    • 84865312335 scopus 로고    scopus 로고
    • Common carotid intima-media thickness measurements in cardiovascular risk prediction: A meta-Analysis
    • Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: A meta-Analysis. JAMA 2012;308:796-803.
    • (2012) JAMA , vol.308 , pp. 796-803
    • Den Ruijter, H.M.1    Peters, S.A.2    Anderson, T.J.3
  • 91
    • 0033533527 scopus 로고    scopus 로고
    • Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
    • Eikelboom JW, Lonn E, Genest J Jr, et al. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
    • (1999) Ann Intern Med , vol.131 , pp. 363-375
    • Eikelboom, J.W.1    Lonn, E.2    Genest Jr., J.3
  • 92
    • 0037164375 scopus 로고    scopus 로고
    • Homocysteine and cardiovascular disease: Evidence on causality from a meta-Analysis
    • Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-Analysis. BMJ 2002;325:1202.
    • (2002) BMJ , vol.325 , pp. 1202
    • Wald, D.S.1    Law, M.2    Morris, J.K.3
  • 93
    • 0037164104 scopus 로고    scopus 로고
    • Homocysteine and risk of ischemic heart disease and stroke: A meta-Analysis
    • Homocysteine Studies Collaboration.
    • Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-Analysis. JAMA 2002;288: 2015-22.
    • (2002) JAMA , vol.288 , pp. 2015-2022
  • 94
    • 0028901371 scopus 로고
    • Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease
    • Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995;15: 232-40.
    • (1995) Arterioscler Thromb Vasc Biol , vol.15 , pp. 232-240
    • Mansoor, M.A.1    Bergmark, C.2    Svardal, A.M.3
  • 95
    • 0035810980 scopus 로고    scopus 로고
    • Homocysteine induces expression and secretion of monocyte chemoattractant protein-And interleukin-8 in human aortic endothelial cells: Implications for vascular disease
    • Poddar R, Sivasubramanian N, DiBello PM, et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-And interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation 2001;103:2717-23.
    • (2001) Circulation , vol.103 , pp. 2717-2723
    • Poddar, R.1    Sivasubramanian, N.2    Di Bello, P.M.3
  • 96
    • 14044276314 scopus 로고    scopus 로고
    • Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function
    • Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 2005;6:27-36.
    • (2005) Curr Drug Metab , vol.6 , pp. 27-36
    • Weiss, N.1
  • 97
    • 17344368557 scopus 로고    scopus 로고
    • Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells
    • Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81.
    • (1997) Arterioscler Thromb Vasc Biol , vol.17 , pp. 2074-2081
    • Majors, A.1    Ehrhart, L.A.2    Pezacka, E.H.3
  • 98
    • 0025095390 scopus 로고
    • Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment
    • Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
    • (1990) Atherosclerosis , vol.81 , pp. 51-60
    • Brattstrom, L.1    Israelsson, B.2    Norrving, B.3
  • 99
    • 77957949167 scopus 로고    scopus 로고
    • Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-Analysis of 8 randomized trials involving 37,485 individuals
    • Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-Analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med 2010;170:1622-31.
    • (2010) Arch Intern Med , vol.170 , pp. 1622-1631
    • Clarke, R.1    Halsey, J.2    Lewington, S.3
  • 100
    • 49949101867 scopus 로고    scopus 로고
    • Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial
    • Ebbing M, Bleie O, Ueland PM, et al.Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008;300:795-804.
    • (2008) JAMA , vol.300 , pp. 795-804
    • Ebbing, M.1    Bleie, O.2    Ueland, P.M.3
  • 101
    • 33645753544 scopus 로고    scopus 로고
    • Homocysteine lowering with folic acid and B vitamins in vascular disease
    • Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354: 1567-77.
    • (2006) N Engl J Med , vol.354 , pp. 1567-1577
    • Lonn, E.1    Yusuf, S.2    Arnold, M.J.3
  • 102
    • 84868518564 scopus 로고    scopus 로고
    • Alteration in lipoproteinassociated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers
    • Ostadal P, Vondrakova D, Kruger A, et al. Alteration in lipoproteinassociated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers. Lipids Health Dis 2012;11:153.
    • (2012) Lipids Health Dis , vol.11 , pp. 153
    • Ostadal, P.1    Vondrakova, D.2    Kruger, A.3
  • 103
    • 82955212740 scopus 로고    scopus 로고
    • Decreased circulating lipoprotein-Associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome
    • Dohi T, Miyauchi K, Okazaki S, et al. Decreased circulating lipoprotein-Associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis 2011;219:907-12.
    • (2011) Atherosclerosis , vol.219 , pp. 907-912
    • Dohi, T.1    Miyauchi, K.2    Okazaki, S.3
  • 104
    • 43049122963 scopus 로고    scopus 로고
    • The effect of darapladib on plasma lipoprotein-Associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study
    • Mohler ER III, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-Associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008;51:1632-41.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1632-1641
    • Mohler III, E.R.1    Ballantyne, C.M.2    Davidson, M.H.3
  • 105
    • 54049152760 scopus 로고    scopus 로고
    • Effects of the direct lipoprotein-Associated phospholipase A (2) inhibitor darapladib on human coronary atherosclerotic plaque
    • Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-Associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82.
    • (2008) Circulation , Issue.118 , pp. 1172-1182
    • Serruys, P.W.1    Garcia-Garcia, H.M.2    Buszman, P.3
  • 106
    • 0023029454 scopus 로고
    • Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
    • Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-38.
    • (1986) JAMA , vol.256 , pp. 2835-2838
    • Castelli, W.P.1    Garrison, R.J.2    Wilson, P.W.3
  • 107
    • 0024501678 scopus 로고
    • High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies
    • Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
    • (1989) Circulation , vol.79 , pp. 8-15
    • Gordon, D.J.1    Probstfield, J.L.2    Garrison, R.J.3
  • 108
    • 36348975228 scopus 로고    scopus 로고
    • Effects of torcetrapib in patients at high risk for coronary events
    • Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl JMed 2007;357:2109-22.
    • (2007) N Engl JMed , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 109
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • dal-OUTCOMES Investigators
    • Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2    Abt, M.3
  • 110
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • AIM-HIGH Investigators
    • AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2
  • 111
    • 38749102779 scopus 로고    scopus 로고
    • High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies
    • van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 634-642
    • Van Der Steeg, W.A.1    Holme, I.2    Boekholdt, S.M.3
  • 112
    • 0022272843 scopus 로고
    • AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission
    • Gualandri V, Franceschini G, Sirtori CR, et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985;37:1083-97.
    • (1985) Am J Hum Genet , vol.37 , pp. 1083-1097
    • Gualandri, V.1    Franceschini, G.2    Sirtori, C.R.3
  • 113
    • 0035901577 scopus 로고    scopus 로고
    • Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: The Limone sul Garda study
    • Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: The Limone sul Garda study. Circulation 2001;103:1949-54.
    • (2001) Circulation , vol.103 , pp. 1949-1954
    • Sirtori, C.R.1    Calabresi, L.2    Franceschini, G.3
  • 114
    • 84155166795 scopus 로고    scopus 로고
    • Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-Type)
    • Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-Type). Atherosclerosis 2012;220:72-77.
    • (2012) Atherosclerosis , vol.220 , pp. 72-77
    • Ibanez, B.1    Giannarelli, C.2    Cimmino, G.3
  • 115
    • 0242577955 scopus 로고    scopus 로고
    • Effect of recombinant ApoAI Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial
    • Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoAI Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-300.
    • (2003) JAMA , vol.290 , pp. 2292-2300
    • Nissen, S.E.1    Tsunoda, T.2    Tuzcu, E.M.3
  • 116
    • 78651379500 scopus 로고    scopus 로고
    • Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
    • Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35.
    • (2011) N Engl J Med , vol.364 , pp. 127-135
    • Khera, A.V.1    Cuchel, M.2    De La Llera-Moya, M.3
  • 117
    • 0041352835 scopus 로고    scopus 로고
    • Asymptomatic cardiac disease following mediastinal irradiation
    • Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42: 743-9.
    • (2003) J Am Coll Cardiol , vol.42 , pp. 743-749
    • Heidenreich, P.A.1    Hancock, S.L.2    Lee, B.K.3
  • 118
    • 4143078308 scopus 로고    scopus 로고
    • Cardiovascular status in long-Term survivors of Hodgkin's disease treated with chest radiotherapy
    • Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-Term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139-48.
    • (2004) J Clin Oncol , vol.22 , pp. 3139-3148
    • Adams, M.J.1    Lipsitz, S.R.2    Colan, S.D.3
  • 119
    • 33748650989 scopus 로고    scopus 로고
    • Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment
    • Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006;24:4100-06.
    • (2006) J Clin Oncol , vol.24 , pp. 4100-4106
    • Harris, E.E.1    Correa, C.2    Hwang, W.T.3
  • 120
    • 33847760275 scopus 로고    scopus 로고
    • Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study
    • Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 2007;99:206-14.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 206-214
    • Swerdlow, A.J.1    Higgins, C.D.2    Smith, P.3
  • 121
    • 0027249771 scopus 로고
    • Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment
    • Orzan F, Brusca A, Conte MR, et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment. Br Heart J 1993;69:496-500.
    • (1993) Br Heart J , vol.69 , pp. 496-500
    • Orzan, F.1    Brusca, A.2    Conte, M.R.3
  • 122
    • 84856736863 scopus 로고    scopus 로고
    • Distribution of coronary artery stenosis after radiation for breast cancer
    • Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 2012;30:380-6.
    • (2012) J Clin Oncol , vol.30 , pp. 380-386
    • Nilsson, G.1    Holmberg, L.2    Garmo, H.3
  • 123
    • 34250703560 scopus 로고    scopus 로고
    • Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
    • Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007;25:43-9.
    • (2007) J Clin Oncol , vol.25 , pp. 43-49
    • Heidenreich, P.A.1    Schnittger, I.2    Strauss, H.W.3
  • 124
    • 73149101321 scopus 로고    scopus 로고
    • Relation of coronary artery calcium score to premature coronary artery disease in survivors .15 years of Hodgkin's lymphoma
    • Andersen R, Wethal T, Gunther A, et al. Relation of coronary artery calcium score to premature coronary artery disease in survivors .15 years of Hodgkin's lymphoma. Am J Cardiol 2010;105:149-52.
    • (2010) Am J Cardiol , vol.105 , pp. 149-152
    • Andersen, R.1    Wethal, T.2    Gunther, A.3
  • 125
    • 84863915229 scopus 로고    scopus 로고
    • The prevention of cardiovascular disease in cancer survivors
    • Daher IN, Daigle TR, Bhatia N, et al. The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J 2012;39:190-8.
    • (2012) Tex Heart Inst J , vol.39 , pp. 190-198
    • Daher, I.N.1    Daigle, T.R.2    Bhatia, N.3
  • 126
    • 46449120787 scopus 로고    scopus 로고
    • Coronary artery disease after radiation therapy for Hodgkin's lymphoma: Coronary CT angiography findings and calcium scores in nine asymptomatic patients
    • Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin's lymphoma: Coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am J Roentgenol 2008;191:32-7.
    • (2008) AJR Am J Roentgenol , vol.191 , pp. 32-37
    • Rademaker, J.1    Schoder, H.2    Ariaratnam, N.S.3
  • 127
    • 32944462609 scopus 로고    scopus 로고
    • Cardiac morbidity of adjuvant radiotherapy for breast cancer
    • Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005;23:7475-82.
    • (2005) J Clin Oncol , vol.23 , pp. 7475-7482
    • Patt, D.A.1    Goodwin, J.S.2    Kuo, Y.F.3
  • 128
    • 0025374837 scopus 로고
    • Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish cancer registry
    • Rutqvist LE, Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish cancer registry. Br J Cancer 1990;61:866-8.
    • (1990) Br J Cancer , vol.61 , pp. 866-868
    • Rutqvist, L.E.1    Johansson, H.2
  • 129
    • 22944477780 scopus 로고    scopus 로고
    • Long-Term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER Cancer Registries
    • Darby SC, McGale P, Taylor CW, et al. Long-Term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER Cancer Registries. Lancet Oncol 2005;6:557-65.
    • (2005) Lancet Oncol , vol.6 , pp. 557-565
    • Darby, S.C.1    McGale, P.2    Taylor, C.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.